INFIGRATINIB PHOSPHATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for infigratinib phosphate and what is the scope of patent protection?
Infigratinib phosphate
is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Infigratinib phosphate has one hundred and thirty-four patent family members in forty countries.
Summary for INFIGRATINIB PHOSPHATE
International Patents: | 134 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Clinical Trials: | 1 |
Patent Applications: | 26 |
DailyMed Link: | INFIGRATINIB PHOSPHATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INFIGRATINIB PHOSPHATE
Generic Entry Date for INFIGRATINIB PHOSPHATE*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for INFIGRATINIB PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 2 |
Emory University | Phase 2 |
US Patents and Regulatory Information for INFIGRATINIB PHOSPHATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-001 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-001 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-001 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INFIGRATINIB PHOSPHATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2005256491 | Pyrimidine urea derivatives as kinase inhibitors | ⤷ Try a Trial |
Malaysia | 194303 | PHARMACEUTICAL DOSAGE FORMS | ⤷ Try a Trial |
Philippines | 12014502593 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL]-1-METHYL-UREA AND SALTS THEREOF | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |